ArticleClinical and translational science2016
Human Embryonic Stem Cell Therapy in Chronic Spinal Cord Injury: A Retrospective Study.
Article in Clinical and translational science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials.BMC medicine · 2022Pooled it
- Clinical application of stem cell therapy in neurogenic bladder: a systematic review and meta-analysis.International urogynecology journal · 2022Pooled it
- Biomaterials and cell-based therapy post spinal cord injury.Journal of translational medicine · 2025Review
- Review
- Establishment of feline embryonic stem cells from the inner cell mass of blastocysts producedRegenerative therapy · 2025Article
- Adverse events of cell therapy clinical trials in human chronic spinal cord injury, a systematic review and meta-analysis.Regenerative therapy · 2024Review
- The Current Update of Conventional and Innovative Treatment Strategies for Central Nervous System Injury.Biomedicines · 2024Review
- Current status and future perspectives on stem cell transplantation for spinal cord injury.World journal of transplantation · 2024Article
- Embryonic stem cells overexpressing high molecular weight FGF2 isoform enhance recovery of pre-ganglionic spinal root lesion in combination with fibrin biopolymer mediated root repair.Stem cell research & therapy · 2024Article
- Challenges in the clinical advancement of cell therapies for Parkinson's disease.Nature biomedical engineering · 2023Review
- Neural Stem Cells Overexpressing Arginine Decarboxylase Improve Functional Recovery from Spinal Cord Injury in a Mouse Model.International journal of molecular sciences · 2022Article
- Pathophysiology and Therapeutic Approaches for Spinal Cord Injury.International journal of molecular sciences · 2022Review
- Progression in translational research on spinal cord injury based on microenvironment imbalance.Bone research · 2022Review
- Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells.Stem cell reviews and reports · 2022Review
- Review
- Induced pluripotent stem cell technology for spinal cord injury: a promising alternative therapy.Neural regeneration research · 2021Article
- Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis.NPJ Regenerative medicine · 2020Article
- Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017).Cell transplantation · 2018Article
- Bone Marrow Very Small Embryonic-Like Stem Cells: New Generation of Autologous Cell Therapy Soon Ready for Prime Time?Stem cell reviews and reports · 2017Article
- Role of physiotherapy in the mobilization of patients with spinal cord injury undergoing human embryonic stem cells transplantation.Clinical and translational medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human embryonic stem cells (hESCs) have a role in treating neurological disorders. The efficacy and safety of hESC in treating spinal cord injury (SCI) was reported in our previous study. In the present study, we have evaluated the efficacy and safety of hESC therapy in 226 patients with SCI. In the first treatment phase (T1), 0.25 mL hESCs were administered intramuscularly twice daily, 1 mL every 10 days i.v., and 1-5 mL every 7 days. Of 153 patients in the American Spinal Injury Association (ASIA) scale A at the beginning of T1, a significant number of patients (n = 80; 52.3%) moved to lower scales at the end of T1 (p = 0.01). At the end of T2, of 32 patients in ASIA scale A, 12 patients (37.5%) moved to scale B (p = 0.01). Of 19 patients, 3 patients (37.5%) moved to scale B at the end of T3 (p = 0.02). No serious adverse events (AEs) were observed. hESC transplantation is safe and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.